Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 27-Sep-2016

Avery Therapeutics, Inc.


Avery was formed in 2014 with the goal of improving the lives of patients with heart failure. Avery was founded by Steven Goldman, MD and Jordan Lancaster, PhD, who invented Avery’s ground breaking MyCardia™ technology specifically to address the clinical need of heart failure, a progressive, debilitating disease with no cure. Avery Therapeutics patented tissue engineering platform for regenerative medicine applications is derived from revolutionary research conducted at the University of Arizona and Nobel Prize winning technology from across the globe. Avery’s technology has the potential to change the way degenerative diseases are treated by going beyond the traditional treatments that manage symptoms to actually solve the underlying cause of the disease—fixing dead or dying cells. Avery’s lead candidate is an engineered cardiac tissue, MyCardia™, for regenerating lost blood vessels and heart muscle in patients with chronic heart failure. There are more than 26 million patients worldwide with heart failure—the number one cause of morbidity and mortality in the developed world—with the number of patients increasing by nearly 15% per year. Avery has extensive pre-clinical data showing safety and efficacy greater than competing technologies and at levels that would result in a quality of life improvement for patients. Avery is on track for clinical trials in heart failure patients starting in 2018. In the future Avery will also pursue products for other human cardiac conditions including dilated cardiomyopathy, arrhythmia and congenital defects as well as similar veterinary applications.


Original YouTube URL: Open

Introduction Video

Additional Questions

Investor questions have not yet been answered for this business